BIO International Convention 2025 trends

Table of contents

Chapter 1: From Manufacturer to Market Maker

Chapter 2: The New Backbone of Biotech

Chapter 3: Science You Can Feel

Chapter 4: Platforms for Every Body

Chapter 5: From Data-Driven to Design-Led

The World Can’t Wait: A Turning Point for Biotech

BIO 2025 brought together over 20,000 leaders from across the global life sciences ecosystem in Boston, a city at the heart of biotech innovation. With attendees from more than 70 countries, the conference highlighted how urgent and interconnected the industry’s challenges and opportunities have become.

This year’s theme: “The World Can’t Wait”, set the tone for a gathering shaped by momentum, scale, and purpose. Across exhibition floors and partnering suites, one thing was clear: biotech is no longer just about discovery. It’s about delivery. A record 62,000+ partnering meetings in just the first day underscored the industry’s shift toward faster, more agile alliances that span R&D, manufacturing, regulatory, and commercialization.

A notable addition to this year’s event was the Storytelling Stage, which elevated the role of brand, communication, and patient voice in shaping the future of biotech.

The rise of narrative thinking once peripheral, has become core to how companies engage investors, regulators, partners, and the public. Science is becoming more accessible, more human, and more urgently tied to trust.

Artificial intelligence also emerged as a key theme, both as a tool of acceleration and as a subject of regulation. Sessions explored how AI is transforming development pipelines, while also prompting essential questions about ethics, transparency, and oversight.

Overall, BIO 2025 reflected a new kind of ambition—one that blends innovation with impact, and speed with responsibility. From cutting-edge therapeutics to bold brand platforms, the companies leading this next chapter are those that connect meaningfully, move quickly, and think holistically.

A Day at BIO 2025

Inspired by true encounters across the show floor.

The sun rises over Boston, casting long shadows across the waterfront as the doors to BIO 2025 swing open. Liza, a CDMO strategist from SK pharmteco, tightens her lanyard and takes her place at the sleek, rebranded booth, just in time to greet a flood of early attendees.

The day begins with quiet ambition. In Innovation Alley, Vanessa of Idevax holds up a microneedle patch and explains how it could stretch limited vaccine stockpiles for global clinics. Nearby, Dr. Lee, a seasoned toxicologist, leans over a chip array demo. “You really think this replaces beagles?” she challenges. Five minutes later, she’s scribbling notes on metabolic dosing subgroups, her worldview already shifting.

Mid-morning, a biotech founder pauses at GlobalData’s booth. Reti and Hannah queue up AI-driven forecasts, sector confidence is dipping, but trendlines point to smarter partnerships. With a few taps, they reveal a matchmaking roadmap that could steer a startup through the fog.

By lunchtime, the espresso machine at Mabion’s booth is working overtime. Anna, a young R&D lead, sips slowly as she listens to how a Polish CDMO scaled up antibody production and just might be the partner she needs. Two aisles over, ProPharma’s Robert demonstrates their CF Box, a futuristic bench-top clean room. “Batch release in minutes,” he says, nodding. “Exact same process in Tokyo or Toronto.” Business cards slip across the counter like handshakes.

The afternoon buzzes with demos, decks, and discovery. At FUJIFILM’s “Partners for Life” showcase, Christine walks delegates through a timeline that spans molecules to manufacturing. At City of Hope’s partnering lounge, Dr. Patel shares a leukemia antibody program ready for Phase I. She maps a pathway from the lab bench to patient bedside, one that blends academic rigor with biotech hustle.

In the final hours, Bill Vincent of Genezen shakes hands with a CAR-T scientist. They swap stories, exchange ideas. Next door, Elena from a Boston startup meets the EMA’s Dr. Tro. “Regulators as partners?” she muses, eyes widening. “That changes everything.”

As the lights dim and the banners lower, bags fill with tote swag, notebooks with ideas, and minds with possibility.

Chapter 1: (CDMO 2.0) From Manufacturer to Market Maker

What’s Happening

CDMOs are moving from backstage players to front-stage storytellers. They’re no longer just manufacturing— they’re shaping narratives, co-owning innovation, and differentiating on partnership, not just price. Scale matters, but soul is what stands out.

Contract Development and Manufacturing Organizations (CDMOs) are rapidly evolving from back-end manufacturers into strategic partners that shape brand narratives, commercial journeys, and innovation roadmaps. Companies like SK pharmteco, Genezen, and FUJIFILM stood out at BIO 2025 by showcasing not just capabilities, but culture emphasizing sustainability, immersive storytelling, and human-centric branding. With SK pharmteco achieving a 99.6% solvent recovery rate and FUJIFILM investing $2 billion in U.S.-based zero-defect sites, the message was clear: infrastructure is the new IP. Agility, transparency, and brand fluency are now expected CDMO differentiators, especially as clients seek speed to market and seamless storytelling across partnerships.

Examples & Signals

$2B Invested

in a U.S. facility by FUJIFILM to deliver “zero-defect” manufacturing and next-gen biologics at scale

99.6%

solvent recovery rate achieved by SK pharmteco —benchmarking sustainability as a CDMO differentiator

Marketing & Brand Takeaway

Humanize your infrastructure. Treat capabilities like characters and projects like shared journeys. Show your science, and the people behind it, with narrative-first branding and experiential design.

1. Co-develop brand narratives with CDMO partners for unified storytelling.
2. Highlight sustainability and flexibility as brand equity, not just operational features.
3. Use behind-the-scenes content to showcase the people and process behind production.
4. Elevate CDMOs on your website and campaigns as brand enablers.
5. Make transparency a visual theme in presentations and packaging.

Chapter 2: (AI as Infrastructure) The New Backbone of Biotech

What’s Happening

AI has matured from promise to platform. Whether enabling remote cleanrooms or shortening timelines from DNA to IND to just nine months, AI is the operational force reshaping biotech. It’s not a tool, it’s a tactic, a talent multiplier, and a trust accelerator.

Artificial Intelligence has shifted from an experimental edge to a foundational layer of biotech infrastructure. At BIO 2025, companies like Thermo Fisher Scientific and ProPharma showcased AI-driven platforms reducing development timelines from DNA to IND to just nine months; an 80% acceleration. These aren’t just technical gains; they’re strategic shifts. AI is enabling predictive modeling, personalized trial design, and robot-run cleanrooms. Regulatory bodies like the EMA are piloting AI-assisted submission workflows, and platforms like GlobalData are reframing raw inputs into strategic insight. This moment isn’t about using AI. It’s about integrating it into every touchpoint of innovation, commercialization, and communication.

Examples & Signals

80% faster IND Cycles

enabled by AI modeling tools (Thermo Fisher Scientific)

9 month DNA to IND Timeline

now achievable with predictive pipelines, setting new development standards

Marketing & Brand Takeaway

Visualize the invisible. Turn backend AI into front-end storytelling: dashboards, motion graphics, transparent claims. Make algorithms feel accessible and reassure audiences through clarity.

1. Translate AI capabilities into user-centric visuals (dashboards, workflows, animations).
2. Brand AI tools with accessible names and benefit-focused taglines.
3. Build messaging around speed, accuracy,and trust—not just the tech.
4. Provide proof through case studieswith outcomes and time savings.
5. Use metaphor and storytelling to make AI emotionally resonant.

Chapter 3: (Format Innovation) Science You Can Feel

What’s Happening

Delivery is being reimagined, from dose to device to demonstration. Whether it’s microneedle skin patches or organs-on-a-chip replacing animal testing, biotech is shifting from lab-first to life-first thinking. It’s innovation with intention, where format drives function and feeling.

New formats are transforming how therapies are delivered, experienced, and perceived. From microneedle skin patches by Idevax that require just 10% of a traditional dose, to “Human-on-a-Chip” platforms replacing unreliable animal testing, delivery is no longer an afterthought, it’s a frontline differentiator. These innovations aren’t just technical, they’re emotional. They address pain points (literally), reduce complexity, and expand global access. Regulators like the EMA are evaluating these formats through a human-centered lens, showing that format is now a strategic conversation in clinical design, branding, and equity.

Examples & Signals

10%

dose delivery via Idevax microneedle patch, reducing pain, cold chain, and cost barriers

>90%

failure rate in animal-tested drugs driving demand for organ-on-chip alternatives

Marketing & Brand Takeaway

Position new formats as acts of empathy. Don’t just talk about efficacy. Highlight ease, access, and emotional impact through UX-inspired messaging and lifestyle-forward visuals.

1. Treat delivery formats as lifestyle innovations: design for ease, not just function.
2. Visually compare old vs. new delivery to highlight improvement.
3. Include patient voices in product demos or digital content.
4. Emphasize portability, comfort, and accessibility in messaging.
5. Build brand identities that reflect care and simplicity.

Chapter 4: (Precision Gets Personal) Platforms for Every Body

What’s happening?

Precision health is leaving the lab and entering real life. From personalized omics to AI-powered wellness tracking, companies like BioAro are making hyper-personalization the new norm. The consumer is no longer a data point, they’re a data partner.

Precision health has moved out of theory and into everyday life. Companies like BioAro are leading a shift from single-source data to dynamic, multi-streamed personalization, blending genomics, microbiomes, wearables, and clinical records. This level of granularity isn’t just about better outcomes.It’s about building trust, relevance, and inclusivity in treatment and engagement. Thermo Fisher Scientific’s AI-optimized pipelines and City of Hope’s community-centered deployment models reflect a broader push: personalization at both the individual and population level. The biotech consumer is no longer a passive recipient. They’re a co-creator of their health journey

Examples & Signals

4+ Health Data Streams

(genomics, microbiome, wearables, history) combined in BioAro’s platform

65% of Patients

now expect personalized treatmentplans as standard, not premium

Marketing & Brand Takeaway

Shift from “platforms that scale” to “platforms that see you.” Use emotion-rich messaging, inclusive imagery, and segmented storytelling to show how precision meets personalization.

1. Segment messaging by audience type and health mindset.
2. Use modular brand systems to personalize visual and verbal identity.
3. Communicate how data improves outcomes and supports inclusion.
4. Show multi-stream data platforms with clarity and value.
5. Lean into personalization as a human, not just clinical, promise.

Chapter 5: (Branding Biotech) From Data-Driven to Design-Led

What’s happening?

At BIO 2025, branding took center stage. From LED-lit booths to bold verbal identities, science-first companies used story, space, and surprise to captivate. It’s not enough to be advanced, you have to feel advanced.

BIO 2025 marked a turning point in how science communicates. Branding was no longer a footnote, it was the headline. From Genezen’s unconventional booth experience to SK pharmteco’s unification of seven legacy divisions under a single brand, biotech companies demonstrated that credibility today requires not just data, but design. With 85% of booths incorporating immersive, interactive storytelling, and 90% of life science buyers reporting that branding influences early trust, the takeaway is clear: people don’t just buy innovation, they buy belief. Branding is now a strategic lever in everything from investor relations to regulatory submissions.

Examples & Signals

7 Legacy Brands Unified

under a bold new SK pharmteco brand system

85% of Booths

at BIO 2025 featured immersive storytelling blending science and brand experience

Marketing & Brand Takeaway

Design for participation, not presentation. Move beyond assets to experiences. Build brands that not only inform but invite, immerse, and inspire.

1. Build immersive touchpoints into booths, websites, and decks.
2. Create brand frameworks that allow for storytelling flexibility.
3. Use content strategy to link brand with trust, not just tech.
4. Train spokespeople to be brand narrators, not just experts.
5. Measure branding’s impact on engagement, awareness, and partnerships.

Final Word: Biotech Means Business

At BIO 2025, the biotech world showed signs of growing up—not in age, but in urgency and alignment. Conversations weren’t just about what’s possible, but what’s scalable, translatable, and impactful. From global CDMOs to AI-driven startups, every player echoed one refrain: science is only meaningful when it moves.

Companies like SK pharmteco and Genezen are bridging innovation and trust through brand unification, digital storytelling, and delivery transparency. FUJIFILM’s massive investments in U.S.-based infrastructure show how legacy brands are positioning themselves as agile, customer-obsessed partners. Meanwhile, Thermo Fisher Scientific’s AI-supported platforms are compressing development timelines, helping biotech companies push to IND faster and more intelligently than ever.

From Human-on-a-Chip’s ethical testing model to Idevax’s pain-free patch, format innovation is reimagining patient experience. BioAro is leading a charge to democratize precision health, turning elite personalization into a daily utility. ProPharma’s modular launch models are helping lean biotechs do more with less. And platforms like GlobalData are proving that insight, not just information, will be the edge that defines the next era of biotech brand leadership.

BIO 2025 confirmed it: the age of pipeline promise has given way to performance branding. 

Thermo Fisher Scientific

The BIO International Convention 2025, as reflected through Thermo Fisher Scientific Scientific’s comprehensive insights, unequivocally indicates an industry characterized by a relentless pursuit of speed and efficiency in drug development, a deepening commitment to integrating sustainability into core operations, and an increasing reliance on collaborative models and pervasive digital technologies like AI and ML. These dynamics collectively underscore a profound transformation underway within the biopharmaceutical sector.

Thermo Fisher Scientific Scientific emerges as a pivotal enabler and thought leader within this evolving landscape. Their strategic focus on integrated solutions, advanced technological capabilities, and fostering strategic partnerships positions them as a critical ally for biopharma companies navigating these complex shifts. The future of biotech will be profoundly defined by agility, interconnectedness, and a holistic approach to health—one that intrinsically encompasses both human well-being and planetary health. The trends discussed at BIO 2025 are not transient but represent foundational shifts that will continue to reshape the industry for the foreseeable future. By aligning its vision and capabilities with these macro trends, Thermo Fisher Scientific Scientific strategically positions itself as an indispensable partner for companies seeking to thrive in this complex and rapidly evolving future. The continuous integration of advanced technologies, the proactive embrace of sustainable practices, and the cultivation of robust collaborative networks will be paramount for success in the coming years, signaling a new era of innovation and responsibility in biopharmaceutical development.

SK pharmteco

SK pharmteco’s strategic rebrand has reinforced its transformation into a partnership-focused CDMO, moving beyond transactional models and harnessing narrative marketing to stand out in a constrained funding environment. Their pioneering sustainability efforts, especially simulated chromatography for 99.6% solvent recycling, demonstrate environmental leadership and client value . Looking ahead, with AI-driven manufacturing integration and an industry poised for consolidation, SK pharmteco is well-positioned to emerge as a top-recognized CDMO within five years.

ProPharma

ProPharma’s CF Box exemplifies the next generation of CGT manufacturing: robot-driven, modular platforms that shrink facility footprints, enforce protocol fidelity via master batch records, and accelerate QA releases from weeks to minutes. By coupling co-development with precision-engineering partners and embedding AI-driven validation, they enable decentralized, patient-proximal production and a continuous-improvement backbone. As ProPharma scales demo sites from Italy to the U.S. and weaves its global team into an end-to-end service network, CF Box stands to reset cost, time, and quality benchmarks across the CGT industry.

Mabion

Mabion leverages its pharmaceutical-heritage expertise and mid-sized scale to address a challenging post-pandemic CDMO market characterized by fewer RFPs and tighter budgets. By specializing in recombinant proteins and monoclonal antibodies while adapting to the rising ADC trend. They fill a niche for agile support to small and mid-stage biotechs. Strategic alliances with BD and Sartorius, plus marquee clients like Novavax and a leading Brazilian partner, underscore their credibility. A focused marketing approach, topped with “great coffee,” and a North Carolina-based BD rep strengthen their U.S. presence, reinforcing Mabion’s “can-do” ethos and client-first flexibility.

Human on a Chip

Human on a Chip is spearheading a paradigm shift in preclinical R&D by delivering integrated, multi-organ microphysiological systems that better predict human responses than animal models. Regulatory endorsement via the FDA’s 2022 Modernization Act and its April 2025 roadmap underscores growing momentum. By de-risking drug portfolios earlier, improving translational success, slashing animal-study costs, and enabling patient-specific stratification these platforms promise faster, more inclusive, and more ethical drug development. As major pharma partners adopt the technology, organ-chips are poised to become core infrastructure across therapeutic areas.

GlobalData

GlobalData positions itself as a one-stop intelligence partner for the pharmaceutical industry, blending deep domain expertise with a unified data platform and consultative services. By distilling vast datasets into strategic insights, covering drug pipelines, clinical trials, manufacturing capabilities, and deal landscapes they empower clients to navigate a funding-constrained, AI-driven environment. Early collaboration, licensing opportunities, strategic intelligence and bespoke rebranding support further differentiate their offering, ensuring that decisions are both data-backed and future-focused.

Genezen

Genezen’s evolution from academia-partnered startup to multi-site CDMO, reflects the broader industry trend toward consolidation and vertical integration in viral-vector manufacturing. Their success rests on forging deep, consultative client partnerships, strategic facility expansions (including retroviral, lentiviral, and AAV capabilities), and openness to next-generation technologies like AI process modeling and needle-free delivery. As the market rebounds, Genezen is well-positioned to scale alongside customer pipelines and drive curative therapies forward.

FUJIFILM

FUJIFILM is uniting its life-science strengths under the “Partners for Life” banner, drawing on over $10 billion in strategic investments and a 91-year legacy of zero-defect manufacturing. By showcasing end-to-end drug-development and manufacturing capabilities, backed by a new $2 billion U.S. facility and emphasizing collaborative country pavilions, CDMO services, and AI-driven processes, FUJIFILM addresses client needs for reliability, agility, and supply-chain resilience. This integrated approach positions FUJIFILM as a trusted, patient-centric partner capable of navigating geopolitical challenges and delivering advanced therapies at scale.

City of Hope

City of Hope exemplifies the next wave of translational medicine by institutionalizing a “hybrid” R&D framework that moves discoveries from bench to bedside more efficiently. Their strategy balances cutting-edge research, strategic acquisitions to expand patient access, and robust industry partnerships supported by diversified funding sources including licensing royalties. By leveraging digital partnering platforms at events like BIO2025, they accelerate deal flow for early-stage assets, all with the ultimate mission of delivering tomorrow’s treatments, today.

BioAri

Bio is positioning itself at the forefront of a paradigm shift toward data-driven, personalized health. By integrating genomics, epigenetics and serial microbiome testing into an AI-powered platform, they have demonstrated tangible performance gains in elite athletes, transforming marginal seconds into podium finishes, and are now scaling the model to wider consumer wellness. Their approach underscores key industry movements: the convergence of multi-omics, the rise of longitudinal monitoring, AI-based personalization, and subscription-driven healthcare services. As costs become more competitive and accessibility improves, Bio exemplifies how precision health can evolve from niche elite sports applications into mainstream preventive medicine.

EMA

EMA is proactively reshaping its engagement strategy to lower barriers for innovators: offering a spectrum of advice formats, targeted incentives for SMEs and orphan-drug developers, and specialized guidance on cutting-edge manufacturing. By fostering global regulatory ties (e.g., with FDA), piloting AI for efficiency gains, and championing the 3Rs in safety testing, EMA aims to accelerate patient-ready products without compromising scientific rigor. The diversification of European biotech clusters and EU funding via the European Innovation Council further reinforce a dynamic, pan-European ecosystem primed for early-stage partnerships.